KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CRISPR Therapeutics AG (CRSP) Preferred Stock Liabilities (2016)

Historic Preferred Stock Liabilities for CRISPR Therapeutics AG (CRSP) over the last 2 years, with Q3 2016 value amounting to $128.6 million.

  • CRISPR Therapeutics AG's Preferred Stock Liabilities changed N/A to $128.6 million in Q3 2016 from the same period last year, while for Sep 2016 it was $128.6 million, marking a year-over-year change of. This contributed to the annual value of $30.4 million for FY2015, which is N/A changed from last year.
  • Latest data reveals that CRISPR Therapeutics AG reported Preferred Stock Liabilities of $128.6 million as of Q3 2016.
  • CRISPR Therapeutics AG's Preferred Stock Liabilities' 5-year high stood at $128.6 million during Q3 2016, with a 5-year trough of $30.4 million in Q4 2015.